Microvast Holdings announces departure of chief financial officer
FORT MYERS - NeoGenomics, Inc. (NASDAQ:NEO) has appointed Dr. Marjorie Green to its Board of Directors, effective June 19, 2025, according to a company press release. The appointment comes as the company, currently valued at $902 million, shows promising signs with analysts expecting profitability this year despite challenging market conditions.
Dr. Green currently serves as Senior Vice President and Head of Oncology, Global Clinical Development at Merck, where she oversees the company’s research in its largest area of commercial revenue and pipeline investment.
Prior to joining Merck, Dr. Green held leadership positions at Seagen as Senior Vice President and Head of Late-Stage Development, and at Genentech as Vice President of Product Development and Global Head of the Breast and Gynecologic Cancer Franchise.
She began her career as a Medical Oncologist and Associate Professor at MD Anderson Cancer Center, later becoming Medical Director of the Nellie B. Connally Breast Center.
"Dr. Green’s deep expertise in clinical oncology and pipeline development, combined with her experience in business development, will be invaluable," said Lynn Tetrault, Chair of the NeoGenomics Board.
NeoGenomics provides cancer genetics testing and information services through a network of CAP-accredited and CLIA-certified laboratories across the United States and in Cambridge, United Kingdom.
The company specializes in diagnostic and predictive testing for oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms.
In other recent news, NeoGenomics reported its Q1 2025 earnings with a revenue of $168 million, falling short of the forecasted $171.35 million. However, the company exceeded expectations with earnings per share (EPS) of $0, against a projected -$0.01. NeoGenomics also recently launched the c-MET CDx diagnostic test for non-small cell lung cancer (NSCLC), which is now available across the U.S. and aligns with the FDA-approved MET-directed therapies. Additionally, NeoGenomics has introduced the PanTracer Family of genomic profiling tests and the Paletrra spatial proteomics platform at the ASCO 2025 meeting, enhancing their precision medicine offerings in oncology.
Moreover, NeoGenomics has fully repaid its $201.25 million convertible debt ahead of schedule, showcasing its financial management capabilities. The company continues to maintain its full-year revenue guidance, projecting a 13-15% growth for 2025. In terms of analyst actions, William Blair and TD Cowen analysts participated in the earnings call, focusing on sales force productivity and Pathline integration timelines. These developments underline NeoGenomics’ ongoing efforts to expand its testing portfolio and strengthen its financial position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.